Dr. Ryan Paul Arnold, D.O. General Practice Medicare: Not Enrolled in Medicare Practice Location: 110 E Gunn Rd, Rochester, MI 48306 Phone: 248-515-1511 |
Dr. Cary S Feldman, General Practice Medicare: Not Enrolled in Medicare Practice Location: 811 Oakwood Dr, Suite 202, Rochester, MI 48307 Phone: 734-459-7444 Fax: 734-459-7755 |
News Archive
Kansas lawmakers on Wednesday announced that they plan to hold hearings to examine a decision made by the administration of Gov. Kathleen Sebelius (D), whom President Obama has nominated as HHS secretary, to increase state payments to a social services group whose board of directors included members with close ties to the governor, the AP/Kansas City Star reports.
Observational epidemiologic studies relating wine and alcohol to health all suffer from the fact that they, of necessity, compare people who prefer certain beverages, but not the beverages themselves. While there have been many intervention trials in animals, randomized trials in humans are less common. Randomized crossover trials, in which each subject receives all interventions in sequence, can be especially important as they tend to avoid baseline differences among subjects and can detect effects of different interventions with smaller numbers of subjects.
At present, a focus on males in basic research and clinical trials means that models of disease are also based on men. Symptoms and disease progression in male patients are therefore considered the standard, while disease manifestations that are usually observed in women are judged "atypical".
Quality Systems, Inc. announced today that its chairman of the board and founder, Sheldon Razin, was named the winner in the software category of TechAmerica's 52nd annual Innovator Awards, which honors eight innovators representing different industry segments for their contributions to the technology industry.
Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, today announced that they have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro.
› Verified 5 days ago